Urolog. pro Praxi, 2009; 10(6): 320-327

Human papillomavirus in urology

MUDr. Ivan Kolombo FEBU1, MUDr. Jaroslav Porš2, MUDr. Martina Poršová3, MUDr. Richard Pabišta3, MUDr. Přemysl Grubský3, MUDr. Jiří Poněšický1, MUDr. Slavomír Blažej1, MUDr. Jan Tobiáš1, MUDr. Josef Kašík1, MUDr. Robert Šverma3, MUDr. Eva Jůzová3, MUDr. Jan Hain4, MUDr. Leoš Gronka5, MUDr. Milan Bartůněk1
1 Centrum robotické chirurgie a urologie Nemocnice Na Homolce, Praha
2 Urologická ambulance Městské nemocnice Turnov
3 Urologické oddělení, Klaudiánova nemocnice, Mladá Boleslav
4 Chirurgické oddělení Městské nemocnice Turnov
5 Urologická poradna Městská nemocnice, Turnov

Human papillomavirus (HPV) is one of the most common cause of sexually transmitted diseases (STD). Genital warts (condylomata accuminata,

venereal warts) are the most easily recognized sign of genital HPV infection. Many people, however, have a genital HPV infection

without genital warts. Infection with certain types of HPV can cause the development of dysplastic epithelial leasions and urogenital malignities

(cervical cancer, vulvar cancer, penile cancer, anal cancer). It is possible to diagnose genital warts just by seeing them. Subclinical

leasions (invisible warts) can be identified by applying vinegar (acetic acid). The best diagnostic method is a PCR method. We only treat

macroscopical leasions. There is no point treating subclinical leasions or trying to eradicate infection from the body. Depending on such

factors as the size and location of the genital warts, we can offer one of several ways to treat them (local application of pharmacs with

cytotoxic or antiviral activity) or we can remove genital warts by cryosurgery (freezing), laser treatment or surgical excision or ablation.

Prevention against against HPV infection is vaccination.

Keywords: human papillomavirus, HPV, condylomata accuminata, cervical cancer, penile cancer, PCR, podophyllin, trichloracetic acid, 5-fluorouracil cream, Aldara, interferons, cryotherapy, laser treatment, surgical excision, vaccination, Cervarix, Silgard.

Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolombo I, Porš J, Poršová M, Pabišta R, Grubský P, Poněšický J, et al.. Human papillomavirus in urology. Urol. praxi. 2009;10(6):320-327.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer. 2004; 91: 935-941. Go to original source... Go to PubMed...
    2. Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 2007; 107(2 Suppl): S27-30. Go to original source... Go to PubMed...
    3. Bafverstedt B. Condylomata acuminata-past and present. Acta Derm Venereol 1967; 47: 376-381. Go to PubMed...
    4. Barrett TJ, Silbar JD, McGinley JP. Genital warts-a venereal disease. JAMA 1954; 154: 333-334. Go to original source... Go to PubMed...
    5. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991; 265: 472. Go to original source...
    6. Berger RE, Lee JC. Sexually transmitted diseases: the clasic diseases. In: Campbell´s Urology CD-Rom, Walsh PC, Retik AB, Vaughan ED, WEin AJ, Volume 1, Section 4, Chapter 17, Copyright 2003, Elsevier Science (USA).
    7. Castellsagué X, Bosch FX, Mu?oz N. The male role in cervical cancer. Salud Publica Mex. 2003; 45(suppl 3): S345-S353. Go to original source... Go to PubMed...
    8. Castellsagué X, Bosch FX, Mu?oz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002; 346: 1105-1112. Go to original source... Go to PubMed...
    9. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89: 101-105. Go to original source... Go to PubMed...
    10. Centers for Disease Control and Prevention. Genital HPV Infection Fact Sheet. Rockville, Md: CDC National Prevention Information Network; 2004.
    11. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, version 2.0. IARC CancerBase No. 5. Lyon, France: IARC Press; 2004.
    12. Freitag P. Papillomavirové infekce v gynekologii. Praha, Triton, 1998; 84.
    13. Freitag P. Low-grade léze děložního hrdla. Praktická gynekologie, 2001; 2: 13-15.
    14. Frisch M, Glimelius B, van den Brule AJC, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997; 337: 1350-1358. Go to original source... Go to PubMed...
    15. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 709-720. Go to original source... Go to PubMed...
    16. Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal Frequency of Imiquimod (Aldara) 5% Cream for the Treatment of External Genital Warts in Immunocompetent Adults: A Meta-Analysis. Sex Transm Dis 2008; 35(4): 346-351. Go to original source... Go to PubMed...
    17. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl). 2004; 193: 35-44. Go to original source... Go to PubMed...
    18. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol. 2006; 108: 1361-1368. Go to original source... Go to PubMed...
    19. Hegarty P, Kayes O, Freeman A, Christopher N, Ralph D, Minahs S. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines, BJU International 2006; 98(3): 526-531. Go to original source... Go to PubMed...
    20. Herbert J, Coffin J. Reducing patient risk for human papillomavirus infection and cervical cancer. J Am Osteopath Assoc 2008; 108(2): 65-70. Go to PubMed...
    21. Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003; 95: 1772-1783. Go to original source... Go to PubMed...
    22. Horenblas S. Lymphadenectomy for squamous cell carcinoma of the penis. Part 2: the role and technique of lymph node dissection. BJU Int 2001; 88(5): 473-483. Go to original source... Go to PubMed...
    23. Ikenberg H, Gissman L, Gross G, et al. Human papillomavirus type-16-related DNA in genital Bowens disease and Bowenoid papulosis. Int J Cancer 1983; 32: 563-569. Go to original source... Go to PubMed...
    24. Kolombo I. Infekce močových cest. www.euni.cz. [online 2008]. http://www.euni.cz/.
    25. Kolombo I, Berndt D, Pabišta R, Smetana L, Porš J, a kol. Problémy současných STD v naší urologické praxi. Urolog. pro Praxi 2004; 5: 29-30.
    26. Kolombo I, Hanuš T, Porš J, Poršová M, Pabišta R, et al. Infekce močových cest pro praktické lékaře a specialisty. Praha: Galén, 2007: 1-281 s.
    27. Kolombo I, Hanuš T, Toběrný M, Beňo P, Valášek P, Rezutka R, Ňaňka O, et al. Prostata v éře robotických technologií. Praha: Pears Health Cyber, s.r.o., 2008: 1-256 s.
    28. Kolombo I, Porš J, Poršová M, Poněšický J, a kol. Infekce lidským papillomavirem (human papillomavirus - HPV). New EU Magazine of Medicine 2008; 2: 51-59.
    29. Kolombo I, Ptáková M, Hanuš T. Chronické infekce močových cest. Lékařské listy Zdravotnických novin 2005; 26: 10-13.
    30. Leijte JAP, Horenblas S. Inguinal metastasis in penile cancer: diagnosis and management. EAU-EBE Update Series 5 (2007): 145-152. Go to original source...
    31. Lillo FB. Human papillomavirus infection and its role in the genesis of dysplastic and neoplastic lesions of the squamous epithelia. New Microbiol. 2005; 28: 111-118. Go to PubMed...
    32. Malek RS, Goellner JR, Smith TF, et al. Human papillomavirus infection and intraepithelial, in situ, and invasive carcinoma of penis. Urol 1993; 42: 159-170. Go to original source... Go to PubMed...
    33. Matoušková M, Hanuš M. Herpetické infekce zevního genitálu. Urolog. pro Praxi 2009; 10(1): 25-28.
    34. McIntosh J, Sturpe DA, Khanna N. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists. J Am Pharm Assoc 2008; 48(1): 1-13. Go to original source... Go to PubMed...
    35. Mellinger BC. Human papillomavirus in the male: An overview. AUA Update Series 1994; Lesson 13, Volume XIII.
    36. Middleman AB. New adolescent vaccination recommendations and how to make them, ,stick". Curr Opin Pediatr 2007; 19(4): 411-416. Go to original source... Go to PubMed...
    37. Monie A, Hung CF, Wu TC. Preventive and therapeutic HPV vaccines. Curr Opin Investig Drugs 2007; 8(12): 1038-1050. Go to PubMed...
    38. Mu?oz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527. Go to original source... Go to PubMed...
    39. Myhre PE, Levy ML, Eichenfield LF, Kolb VB, Fielder SL, Meng TC. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. Pediatr Dermatol 2008; 25(1): 88-95. Go to original source... Go to PubMed...
    40. Novara G, Galfano A, De Marco V, Artibani W, Ficarra V. Prognostic factors in squamous cell carcinoma of the penis. Nat Clin Pract Urol 2007; 4(3): 140-146. Go to original source... Go to PubMed...
    41. Oriel JD, Almeida JD. Demonstration of virus particles in human genital warts. Br J Vener Dis 1970; 37: 37. Go to original source... Go to PubMed...
    42. Persson B, Sjödin JG, Holmberg L, Windahl T, Steering Committee of the National Penile Cancer Register in Sweden. The National Penile Cancer Register in Sweden 2000-2003. Scand J Urol Nephrol 2007; 41(4): 278-282. Go to original source... Go to PubMed...
    43. Poněšický J, Kolombo I, Porš J, Poršová M, a kol. Karcinom penisu. Standardní postup diagnostiky a léčby. Nové Směry. Urolog. pro Praxi 2009; 10(1): 29-33.
    44. Poršová M, Porš J, Kolombo I, Pabišta R. Lidský papilomavirus a jeho klinické projevy. Urolog pro Praxi 2006; 6: 267-269.
    45. Poršová M, Porš J, Kolombo I, Pabišta R. Prostatický syndrom. Urolog pro Praxi 2006; 1: 24-27.
    46. Siegel JF, Mellinger BC. Human papillomavirus in the male patient. Urol Clin N Amer 1992; 19: 83-91. Go to original source...
    47. Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of Type-Specific Immunoassays to Evaluate the Functional Immune Response to GARDASIL(R), a Vaccine for Human Papillomavirus Types 16, 18, 6, and 11. Hum Vaccin 2007; 4; 2-4. Go to original source... Go to PubMed...
    48. Svare EI, Kjaer SK, Worm AM, ?sterlind A, Meijer CJ, van den Brule AC. Risk factors for genital HPV DNA in men resemble those found in women: A study of male attendees at a Danish STD clinic. Sex Transm Infect. 2002; 78: 215-218. Go to original source... Go to PubMed...
    49. Syed TA, Ahmadpour OA, Ahmad SA, Shamsi S. Treatment of genital herpes in males with imiquimod 1% cream: a randomised, double-blind, placebo-controlled study. Clin Drug Investig 1998; 16(3): 187-191. Go to original source... Go to PubMed...
    50. Syrjanen KJ, Heinonen UM, Kauraniemi T. Cytologic evidence of the association of condylomatous lesions with dysplastic and neoplastic changes in the uterine cervix. Acta Cytol 1981; 25: 17. Go to original source...
    51. Šťáva Z. Kožní choroby vyvolané viry. In: Záruba F, et al. Dermatovenerologie Praha: Karolinum 1992: 226-238.
    52. Van Opphofen A, Schöfer H, Henke U, Lenz T, Eul A. Randomisierte Vergleichsstudie zur anhaltenden Wirksamkeit von Imiquimod 5% Creme versus konventionelle ablative Methoden bei anogenitalen Condylomata acuminata. In: 59. Kongress der Deutschen Gesellschaft für Urologie; 2007; Abstrakt V. 20.1. Berlin; 2007.
    53. Villa L, Costa R, Petta R, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. Br J Cancer. 2006; 95: 1459-1466. Go to original source... Go to PubMed...
    54. Wagenlehner F. Latest development in infections in urology. Eur Urol Today 2008; 1: 11.
    55. Weiner JS, Edison TL, Walther PJ. Oncogenic human papillomavirus type 16 is associated with squamous cell cancer of the male urethra. Cancer Research 1992; 52: 5018-5023. Go to PubMed...
    56. World Health Organization. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting, 16-18 February 1999. Geneva, Switzerland: World Health Organization; 1999: 1-22.
    57. World Health Organization. Report of the Consultation on Human Papillomavirus Vaccines 2005. Geneva, Switzerland: World Health Organization Report; 2005: 1-38.
    58. Workovski KA. The 1998 CDC sexually transmitted diseases treatment guidelines. Curr Infect Dis Rep 2000; 2: 44. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.